Do you want to read an article? Please log in or register.
Five-Year Follow-Up of the Phase III ASCOT Trial of Adjuvant S-1 After Resection for Biliary Tract Cancer
Gastrointestinal Cancer
Related content
Breast Cancer
A Randomized Phase III Trial of Anthracyclines Followed by Taxane versus Taxane Plus Carboplatin as (Neo)Adjuvant Therapy in Patients with Triple-Negative Breast Cancer: KCSG BR 15-1 PEARLY Trial
Ann Oncol
Kim GM, Jung KH, Jeung HC, Lee J, Lee KS, Im SA, Kang SY, Kim SH, Kim HJ, Park KH, Chae YS, Koh SJ, Cho EK, Park KU, Lee SS, Kim JY, Choi IS, Baek SK, Moon YW, Kim SG, Lim ST, Lee KH, Kim HJ, Kim MH, Kim KH, Kim SI, Park S, Park HS, Kim JY, Kim YB, Kim SB, Ahn JH, Jeong JH, Kim JH, Jeong J, Park WC, Sim SH, Lee K, Nam CM, Park S, Paik S, Sohn J, Korean Cancer Study Group (KCSG)
doi: 10.1016/j.annonc.2026.05.703
RECOMMENDED
Breast Cancer
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1
★ 1
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Offersen BV, Alsner J, Høgsbjerg K, Nielsen HM, Maae E, Nielsen MH, Mjaaland I, Maraldo MV, Kirkove C, Lörincz T, Al-Rawi S, Blix ES, Schreiber A, Krause M, Kasti UM, Matthiessen LW, Kronborg C, Tramm T, Jensen MB, Overgaard J, DBCG RT Committee
doi: 10.1200/JCO-25-02705
RECOMMENDED
Breast Cancer
Adjuvant Epirubicin Plus Cyclophosphamide Followed by Taxanes With or Without Carboplatin in Early-Stage Triple-Negative Breast Cancer (RJBC 1501): A Randomized Phase III Trial
★ 3
Recommended by
Prof. Dr Beat Thürlimann, Faculty Member
J Clin Oncol
Chen X, Huang J, Shi H, Zhu J, Wu W, Ye G, He Q, Shi Y, Zhang A, Xie X, Wang X, Chen X, Wu W, Wu J, Li Z, Li Z, Dai Y, Ren W, Shao Q, Chen Y, Zeng Y, Zhang F, Dong S, Pegram MD, Shen K
doi: 10.1200/JCO-25-02412
Genitourinary Cancer
Bladder Adjuvant Radiotherapy: Phase III Multicenter Randomized Controlled Trial of Adjuvant Radiotherapy or Observation for Postcystectomy Muscle-Invasive Bladder Cancer
J Clin Oncol
Murthy V, Maitre P, Pal M, Arora A, Phurailatpam R, Sharma R, Gudipudi D, Rajappa S, Pujari L, Bandekar B, Joseph D, Kannan S, Krishnatry R, Misra A, Joshi A, Noronha V, Prabhash K, Menon S, Bakshi G, Prakash G
doi: 10.1200/JCO-25-02093
Gastrointestinal Cancer
Time-dependent recurrence patterns after curative resection for stage II/III colorectal cancer: An integrated analysis of four phase III randomized controlled trials (JCOG2310A-S4)
Eur J Cancer
Tashiro K, Osumi H, Kataoka K, Shimada Y, Inomata M, Hamaguchi T, Takii Y, Suwa Y, Mizusawa J, Sano Y, Suto T, Murata K, Adachi T, Ueno H, Ikeda S, Komori K, Shiozawa M, Tsukamoto S, Takashima A, Kanemitsu Y
doi: 10.1016/j.ejca.2026.116957
RECOMMENDED
Breast Cancer
Sustained benefit of adjuvant olaparib in women with germline BRCA1- and BRCA2- -associated high-risk HER2-negative early breast cancer: Updated results from the OlympiA phase III trial
★ 3
Recommended by
Dr Andreas Müller, Faculty Member
Ann Oncol
Garber JE, Cameron D, Campbell C, Yothers G, Taboada M, El-Abed S, Rastogi P, McConnell R, Correa A, Delaloge S, Liu WT, Sharma P, Bergh J, Janni W, Balmaña J, Loman N, Španić T, Friedman S, Freeman T, Armstrong A, Korde L, Im S, Sagara Y, Viale G, Bliss J, Gianni L, Jóhannsson Ó, Zoppoli G, De Dueñas EM, Marmé F, Fein L, Arnedos M, Ford J, Schmutzler R, Loibl S, Linderholm B, Lakhani SR, Gnant M, Gelmon K, Domchek SM, Senkus E, Eisen A, Jager A, Piccart M, Phillips KA, Traina T, Stickeler E, Singer CF, Shao Z, Liu X, Tipping H, Aktan G, Martinez M, Canon JL, Takahashi M, Yasojima H, Middleton K, Pristauz-Telsnigg G, Pfeiler G, Virani S, Valdes-Albini F, Wolmark N, Mesa ID, Paterson V, Gelber RD, Geyer CE Jr, Tutt ANJ
doi: 10.1016/j.annonc.2026.08.002
Lung, Respiratory and Thoracic Cancer
Aumolertinib as adjuvant therapy in resected EGFR-mutated non-small-cell lung cancer (ARTS): a double-blind, multicentre, randomised, controlled, phase 3 trial
Lancet Oncol
Zhang L, Zhang X, Wu L, Xing W, Liu C, Zhang P, Chen K, Shi J, Xu S, Zhang X, Dong X, Fang H, Yu X, Gao Y, Li G, Chen Z, Fan S, Zhang X, Cheng Y
doi: 10.1016/S1470-2045(25)00643-6
Gastrointestinal Cancer
Durvalumab Plus Chemotherapy for Advanced Biliary Tract Cancer: A Post Hoc Analysis of the TOPAZ-1 Randomized Clinical Trial
JAMA Oncol
Oh DY, He AR, Qin S, Chen LT, Okusaka T, Griffin R, Wang J, Xynos I, Vogel A, Valle JW
doi: 10.1001/jamaoncol.2026.2204
Gastrointestinal Cancer
Neoadjuvant nab-paclitaxel plus gemcitabine followed by modified FOLFIRINOX for resectable pancreatic cancer: A randomized phase 3 trial
Cancer Cell
Bai X, Li X, Chen Y, Qiao G, Zhang Q, Ma T, Gao S, Zhang M, Shen Y, Wu J, Yu J, Que R, Zhang X, Sun K, Xiao W, Jiang T, Liang T
doi: 10.1016/j.ccell.2025.09.009